Renal Denervation Downer: Medtronic’s Pivotal Trial Misses Efficacy Endpoint
This article was originally published in The Gray Sheet
Executive Summary
The firm’s SYMPLICITY HTN-3 trial failed to meet its primary efficacy endpoint, scuttling Medtronic’s plans to earn a PMA for renal denervation this year. The primary investigator for the trial acknowledges in an interview that the finding raises serious questions for the future of renal denervation in hypertension.